跳至主要内容
临床试验/ITMCTR2200005511
ITMCTR2200005511尚未招募4 期

Suhuang antitussive capsule in the treatment of bronchial asthma--a multi-center, randomized, double-blind, placebo-controlled clinical study

Shanghai General Hospital0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 60(—)
性别
All

入选标准

  • (1) Outpatients with chronic persistent of asthma who meet the typical asthma diagnostic criteria in the 2020 edition of the Guidelines for the Prevention and Treatment of Bronchial Asthma;
  • (2) The severity is graded as mild or moderate, and the ACT score is =19 points;
  • (3) Age from 18 to 60 years old;
  • (4) Sign the informed consent form.
  • Those who meet all the above criteria at the same time can be included in the study.

排除标准

  • (1) Combined use of compound methoxyphenamine capsules, codeine tablets, codeine oral solution, compound pseudoephedrine hydrochloride oral solution, tabellae dextpomethorphani hydrobromiditablets, compound licorice tablets, Jizhi syrup, Shedan Chuanbei loquat ointment, Xianzhuli Oral Liquid, Qutanling Oral Liquid, Qutan Zhike capsules, Fei Li Ke Mixture, Xuanfei Zhisou Mixture and other medicines containing anti-cough ingredients, or Maxing Zhike Tablets, Gejie Dingchuan Pills and other Chinese traditional medicines containing ephedra ingredients within 2 weeks;
  • (2) Patients with a history of arrhythmia, coronary atherosclerotic heart disease, hypertension or hyperthyroidism, and poor control;
  • (3) Patients with severe heart, liver, kidney, brain, mental, or neurological diseases;
  • (4) Allergic to drugs known in this study;
  • (5) Pregnant or lactating women or those planning pregnancy;
  • (6) Those who have participated in or are participating in other clinical trials within 28 days;
  • (7) Those who are deemed unsuitable to participate in this trial by the researcher.
  • Those who meet any of the above criterion cannot be included in this study.

研究者

相似试验